Akebia Therapeutics (AKBA) News Today → $5,000 Gold? (From Stansberry Research) (Ad) Free AKBA Stock Alerts $1.30 +0.06 (+4.84%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAkebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)finanznachrichten.de - May 2 at 10:01 AMAkebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlightsprnewswire.com - May 2 at 8:30 AMAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)prnewswire.com - May 1 at 4:05 PM4 Biotech Stocks to Watch Closely in Maystocknews.com - April 30 at 6:04 PMAkebia Therapeutics (NASDAQ:AKBA) Downgraded by StockNews.com to "Hold"americanbankingnews.com - April 30 at 5:32 AMAkebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.commarketbeat.com - April 29 at 11:19 PMWhen Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?finance.yahoo.com - April 28 at 12:27 PMAkebia Therapeutics (NASDAQ:AKBA) Share Price Crosses Below Two Hundred Day Moving Average of $1.34americanbankingnews.com - April 27 at 4:02 AMAkebia Therapeutics (NASDAQ:AKBA) Lifted to "Buy" at StockNews.commarketbeat.com - April 19 at 11:04 PMAkebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Up 32.3% in Marchmarketbeat.com - April 13 at 10:59 AMAkebia Therapeutics (NASDAQ:AKBA) Downgraded by StockNews.commarketbeat.com - April 11 at 2:15 AMAkebia Therapeutics Surges on FDA Approval for Anemia Treatmentmarketbeat.com - April 3 at 3:04 PMAkebia Therapeutics Surges on FDA Approval for Anemia Treatmentmarketbeat.com - April 3 at 9:11 AMAkebia Therapeutics (NASDAQ:AKBA) Upgraded by StockNews.com to Buymarketbeat.com - April 3 at 2:11 AMBiggest stock movers today: AMC, PLTR, RH, and moremsn.com - March 29 at 9:38 AMFDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemiafinance.yahoo.com - March 28 at 1:35 PMAkebia Therapeutics (NASDAQ:AKBA) Price Target Raised to $6.00marketbeat.com - March 28 at 12:32 PMAkebia stock jumps as FDA clears renal anemia therapymsn.com - March 28 at 8:34 AMAkebia's Vafseo Tablets Approved By FDA For Anemia Treatment In Dialysis Patientsmarkets.businessinsider.com - March 28 at 1:47 AMTwo years after initial rejection, Akebia’s anemia drug finally gets FDA approvalbizjournals.com - March 28 at 1:47 AMU.S. FDA approves Akebia's anemia drugreuters.com - March 27 at 8:45 PMAkebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysisprnewswire.com - March 27 at 8:26 PMAkebia Awaits FDA Word On Second Crack At Vadadustatfinance.yahoo.com - March 27 at 10:46 AMStock Traders Buy High Volume of Call Options on Akebia Therapeutics (NASDAQ:AKBA)marketbeat.com - March 22 at 1:40 PMInvestors Buy High Volume of Put Options on Akebia Therapeutics (NASDAQ:AKBA)marketbeat.com - March 19 at 11:21 AMAkebia Therapeutics (NASDAQ:AKBA) Rating Increased to Buy at StockNews.commarketbeat.com - March 18 at 11:17 PMAkebia Therapeutics' (AKBA) Buy Rating Reiterated at HC Wainwrightmarketbeat.com - March 18 at 3:10 PMAkebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33finance.yahoo.com - March 17 at 1:30 PMAkebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectationsfinance.yahoo.com - March 16 at 12:10 PMBuy Rating for Akebia Therapeutics Amid Anticipated Approval of Anemia Drug Vadadustat and Strong Financial Positionmarkets.businessinsider.com - March 15 at 9:07 PMAkebia Therapeutics (NASDAQ:AKBA) Releases Quarterly Earnings Results, Meets Estimatesmarketbeat.com - March 15 at 9:21 AMUS Life & Non-Life Insurance Market Poised for Strong Growth: In-Depth Analysis Unveiledfinance.yahoo.com - March 15 at 8:44 AMAKBA Stock Earnings: Akebia Therapeutics Beats Revenue for Q4 2023investorplace.com - March 14 at 10:04 PMRecap: Akebia Therapeutics Q4 Earningsbenzinga.com - March 14 at 7:43 PMAkebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarterfinance.yahoo.com - March 14 at 7:43 PMAkebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlightsprnewswire.com - March 14 at 4:15 PMAkebia Therapeutics earnings: here's what Wall Street expectsmarkets.businessinsider.com - March 14 at 8:08 AMEarnings Preview For Akebia Therapeuticsbenzinga.com - March 13 at 3:51 PMAkebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Resultsfinance.yahoo.com - March 11 at 5:10 PMAkebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Resultsprnewswire.com - March 11 at 5:05 PMAkebia Therapeutics, Inc. (NASDAQ:AKBA) COO Sells $13,684.38 in Stockmarketbeat.com - March 1 at 7:13 PMAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)prnewswire.com - March 1 at 4:05 PMAkebia Therapeutics (NASDAQ:AKBA) Stock Crosses Above 50 Day Moving Average of $1.45marketbeat.com - February 23 at 4:55 AMAkebia Therapeutics Stock (NASDAQ:AKBA), Short Interest Reportbenzinga.com - February 22 at 11:28 PMAKBA Mar 2024 1.500 putfinance.yahoo.com - February 17 at 12:04 PMAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - February 2 at 7:44 PMSteven Keith Burke Sells 24,311 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stockmarketbeat.com - February 2 at 6:58 PMAkebia Therapeutics, Inc. (AKBA)finance.yahoo.com - February 2 at 2:39 PMFY2023 Earnings Forecast for Akebia Therapeutics, Inc. (NASDAQ:AKBA) Issued By HC Wainwrightmarketbeat.com - February 2 at 7:40 AMAkebia Therapeutics Secures $55M Credit Facility with Kreos Capitalmsn.com - January 31 at 8:30 PM Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address $5,000 Gold? (Ad)Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now). Find out how to do right here in this free video. AKBA Media Mentions By Week AKBA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKBA News Sentiment▼0.670.33▲Average Medical News Sentiment AKBA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKBA Articles This Week▼82▲AKBA Articles Average Week Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RENB News EPIX News VRCA News ERAS News NLTX News KMDA News HOWL News RAPT News ENTA News VNDA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKBA) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingA once-in-a-century investment opportunityStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
